SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 319.63 |
| Enterprise Value ($M) | 268.26 |
| Book Value ($M) | 32.22 |
| Book Value / Share | 0.70 |
| Price / Book | 9.92 |
| NCAV ($M) | 26.50 |
| NCAV / Share | 0.58 |
| Price / NCAV | 12.06 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.27 |
| Return on Assets (ROA) | -0.62 |
| Return on Equity (ROE) | -1.19 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.23 |
| Current Ratio | 3.23 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 120.66 |
| Assets | 126.38 |
| Liabilities | 94.16 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Barclays Plc | 8.87 | ||
| 13G | Balyasny Asset Management Llc | 8.87 | ||
| 13G/A | Alyeska Investment Group, L.P. | 2.10 | -65.03 | |
| 13G/A | Biotechnology Value Fund L P | 9.99 | 9.98 | |
| 13G/A | Nantahala Capital Management, LLC | 9.99 | ||
| 13G/A | Stonepine Capital Management, LLC | 4.80 | -16.65 | |
| 13G/A | Soleus Capital Master Fund, L.P. | 7.30 | 135.03 | |
| 13G | Vanguard Group Inc | 5.19 | -73.88 | |
| 13G | Hirschman Orin | 6.10 | ||
| 13G/A | Orbimed Advisors Llc | 9.90 | 171.32 | |
| 13G/A | Soleus Private Equity Fund III, L.P. | 8.70 | ||
| 13G/A | Flynn James E | 0.00 | -100.00 | |
| 13G/A | Viking Global Investors Lp | 0.00 | -100.00 | |
| 13G/A | Adage Capital Management, L.P. | 0.00 | ||
| 13G | BlackRock, Inc. | 5.60 | 0.00 | |
| 13G/A | Vivo Opportunity, LLC | 6.10 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES | ||
| UNITED STATES | ||
| UNITED STATES | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 538,354 | 1,200,950 | 44.83 | |
| 709,323 | 2,135,140 | 33.22 | |
| 302,608 | 1,016,633 | 29.77 | |
| 828,349 | 2,097,717 | 39.49 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| VINC – Vincerx Pharma, Inc. | VKTX – Viking Therapeutics, Inc. |
| VRPX – Virpax Pharmaceuticals, Inc. | VTGN – Vistagen Therapeutics, Inc. |
| VTVT – vTv Therapeutics Inc. |